Kiromic BioPharma, Beverly Hills Cancer Center to Partner on Clinical Trials


Treatment facility to be the first to evaluate Deltacel for patients with non-small cell lung cancer.

Doctor congratulating to his medical assistant. Image Credit: Adobe Stock Images/focusandblur

Image Credit: Adobe Stock Images/focusandblur

Kiromic BioPharma announced that it has agreed to terms for Beverly Hills Cancer Center (BHCC) to serve as the inaugural clinical site for the evaluation of Deltacel (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, gamma delta t-cell (GDT) therapy, in patients with non-small cell lung cancer. BHCC includes a radiation oncology center, an infusion center, a full-service diagnostic imaging center (featuring MRI, CT, PET/CT), a diagnostic laboratory, and has previously conducted multiple clinical trials across multiple cancer types.

“As our clinical research program embarks on this groundbreaking clinical journey, we envision a future where patients have access to pioneering therapies and renewed hope in their battle against cancer. For years, BHCC has remained at the forefront of medical excellence, continually seeking innovative approaches to redefine the future of cancer treatment. We are very excited about this collaboration with Kiromic, a very forward-thinking and innovative company, and about this new therapeutic approach and the potential to contribute to science with the ultimate goal of improving the lives of cancer patients worldwide,” said Afshin Eli Gabayan, MD, medical director, principal investigator, Beverly Hills Cancer Center and Assistant Clinical Professor at UCLA-David Geffen School of Medicine.

Reference: Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement. BusinessWire. October 23, 2023. Accessed October 23, 2023.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.